1. Home
  2. HXHX vs INDP Comparison

HXHX vs INDP Comparison

Compare HXHX & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HXHX

Haoxin Holdings Limited Class A Ordinary Shares

HOLD

Current Price

$0.86

Market Cap

6.2M

Sector

Industrials

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.45

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HXHX
INDP
Founded
2003
2000
Country
China
United States
Employees
85
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
5.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
HXHX
INDP
Price
$0.86
$2.45
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.5M
2.2M
Earning Date
05-20-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$0.27
52 Week High
$1.84
$13.24

Technical Indicators

Market Signals
Indicator
HXHX
INDP
Relative Strength Index (RSI) 72.66 51.60
Support Level $0.41 $1.86
Resistance Level $0.92 $2.70
Average True Range (ATR) 0.13 0.80
MACD 0.03 0.10
Stochastic Oscillator 67.90 28.97

Price Performance

Historical Comparison
HXHX
INDP

About HXHX Haoxin Holdings Limited Class A Ordinary Shares

Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: